Methylmalonic aciduria is a human autosomal recessive disorder of organic acid metabolism resulting from a functional defect in the activity of the enzyme methylmalonyl-CoA mutase. Based upon the homology of the human mutase locus with the mouse locus, we have chosen to disrupt the mouse mutase locus within the critical CoA binding domain using gene-targeting techniques to create a mouse model of methylmalonic aciduria. The phenotype of homozygous knock-out mice (mut ؊/؊ ) is one of early neonatal lethality. Mice appear phenotypically normal at birth and are indistinguishable from littermates. By 15 h of age, they develop reduced movement and suckle less. This is followed by the development of abnormal breathing, and all of the mice with a null phenotype die by 24 h of age. Urinary levels of methylmalonic and methylcitric acids are grossly increased. Measurement of acylcarnitines in blood shows elevation of propionylcarnitine with no change in the levels of acetylcarnitine and free carnitine. Incorporation of [ 14 C]propionate in primary fibroblast cultures from mut ؊/؊ mice is reduced to approximately 6% of normal level, whereas there is no detectable synthesis of mut mRNA in the liver. This is the first mouse model that recapitulates the key phenotypic features of mut 0 methylmalonic aciduria.
methylmalonic aciduria.
Methylmalonic aciduria (MMA, 1 MIM 251000) is an autosomal recessive inborn error of organic acid metabolism. The true incidence of the disorder has been difficult to determine, and variable figures have been reported. A recent review of newborn screening data indicates an incidence of isolated MMA (mutase and cobalamin A/B) in the order of 1 in 140,000 in Australia (1) . The condition results from a functional defect in the enzyme methylmalonyl-CoA mutase (MCM, EC 5.4.99.2) either due to a defect in the mutase (mut) gene itself (designated mut o or mut Ϫ ) or from a defect in the metabolism of the cofactor adenosylcobalamine. MCM is a nuclear-encoded mitochondrial enzyme that catalyzes the conversion of L-methylmalonyl-CoA to succinyl-CoA, which then enters the citric acid cycle. L-Methylmalonyl-CoA is predominantly derived from the catabolism of branched chain amino acids in the diet, odd chain fatty acids via propionyl-CoA, and propionate synthesized from gut flora.
Following normal pregnancy and delivery-affected individuals with the mut 0 form typically present in the newborn period with overwhelming illness consisting of acidosis, vomiting, poor feeding, hypotonia, and lethargy. Untreated, there is progression to coma and death. The mut 0 form may have a less severe phenotype. Aggressive supportive therapy results in survival. However, any intercurrent illness or "metabolic stress" may lead to metabolic instability characterized by repeat recurrent life-threatening episodes of metabolic decompensation.
Currently, the mainstay of treatment for MMA is strict dietary restriction and drug manipulation. The aim of such treatment is to control methylmalonate (MM) and propionate production by limiting dietary intake of precursors and endogenous production of substrate by catabolism. Despite such treatment, morbidity and mortality remain high (2) . There are many long term complications such as poor appetite and growth, pancreatitis, cardiomyopathy, and metabolic stroke resulting in permanent neurological damage. Individuals that survive infancy develop renal failure later in childhood and adolescence (3) . The underlying pathophysiology leading to these complications is poorly understood.
Liver and combined liver/kidney transplantations have been attempted with the aim of replacing the deficient enzyme activity, thus preventing the need for diet and avoiding the long term complications. The outcome of such treatment has been successful in allowing patients to relax the dietary restrictions and preventing acute metabolic decompensations (4). However, the natural history of the renal failure and propensity to metabolic stroke remain unclear at this stage (5) . Furthermore, liver transplantation is restricted because of the risks associated with it as well as the limitation of suitable donors. A better understanding of the pathophysiology of the disease is therefore needed to enable the development of an effective therapy for this disorder. However, progress has been limited by the lack of animal models for this disorder.
The human mutase gene is ubiquitously expressed and encodes for a 750 amino acid precursor protein including a 32 amino acid mitochondrial leader sequence (6, 7). The leader sequence is cleaved within the mitochondria, and a mature enzyme is formed. Three functional domains have been proposed as follows: (i) the C terminus (residues 578 -750), which comprises the cobalamin binding domain; (ii) the (␤/␣) 8 barrel (residues 87-416) to which the CoA of methylmalonyl-CoA binds; and (iii) the N terminus with a region involved in the dimerization of the two MCM monomers (residues 32-87). Cloning of the mouse locus revealed a 94% homology to the human amino acid sequence (8) . Furthermore, the mouse cDNA was shown to complement patient cell lines, thus confirming its homology at a functional level.
To develop a mouse model for mut 0 MMA, we have disrupted the mouse mutase locus by gene targeting. We have chosen to disrupt the mouse locus within the CoA binding domain by replacement of exon 3 with an antibiotic selection marker by homologous recombination. This is the first mouse model to be developed for the mut Ϫ/Ϫ form of MMA disease. Here we describe the observed phenotype and the biochemical characterization of these mice.
EXPERIMENTAL PROCEDURES
Construction of Targeting Cassette-The primers 2aF, 5Ј-TGGGAG-TATTCATGCTTCAC-3Ј, and 2aR, 5Ј-CTGCATACTGACGGATGGTC-3Ј, were designed to amplify a 349-bp product encompassing mouse mutase exon 2. Similarly, the primers 13F, 5Ј-ATGGATCCTCAGCCA-GACC-3Ј, and 13R, 5Ј-TGTATACAGATCAGCGTGTTTC-3Ј, were designed to amplify a 280-bp product encompassing mouse exon 13. The mouse exon 2 and exon 13-specific PCR products were used as probes to screen the RPCI-23 mouse BAC library (BACPAC Resources, Oakland, CA). Among the clones identified, the BAC clone 38D7 (RPCI-23; 38D7, 100 kb) appeared to contain the entire mouse mutase locus. The targeting vector was constructed by subcloning an 11.2-kb NheI/BamHI restriction digestion fragment containing exons 2-5 of the mouse mutase locus from BAC clone 38D7 into the tetracycline resistance gene of the pBR322 plasmid. Insertion of this fragment disrupted the tetracycline resistance gene and produced pBR_mutA (data not shown). A 1468-bp fragment containing exon 3 and flanking intronic sequence was deleted from pBR_mutA by NcoI restriction digestion and replaced with an antibiotic selection cassette to disrupt the CoA binding domain (Fig.  1A) . The 1.55-kb neomycin/kanamycin antibiotic selection cassette was amplified by PCR from the plasmid pEGFP-N22 (9) using primers LNK-F, 5Ј-AATATTTAAATAACTTCGTATAGCATACATTATACGAA-GTTATATTCTAAATACATTCAAATAT-3Ј, and LNK-R, 5Ј-AATATTT-AAATATAACTTCGTATAATGTATGCTATACGAAGTTATGAACAAA-CGACCCAACA-3Ј, with attached loxP sites (underlined sequence). The selection cassette was gel-purified and cloned into the NcoI sites of pBR_mutA using TA cloning to produce pBR_mutB (Fig. 1B) . Clones containing the selection cassette in the reverse orientation were used for targeting into embryonic stem (ES) cells. This construct when homologously recombined into the mouse mutase locus should cause deletion of exon 3 (Fig. 1C) . If the selection cassette is spliced out by splicing between exons 2 and 4, it should produce a frameshift with premature protein truncation and total loss of enzyme function.
Generation and Microinjection of Targeted Embryonic Stem CellsMouse ES cells from a W9.5 line were used for transfection. Cells (5 ϫ 10 7 ) were electroporated with 30 g of pBR_mutB DNA, which had been linearized by restriction digestion with EcoRV. Settings were 0.8 kV, 3 microfarads, and maximum ⍀ using a Bio-Rad gene pulser (Bio-Rad). Transfected ES cells were grown on STO Neo R feeder cells using standard ES medium containing leukemia inhibitory factor (Chemicon Inter- ) (lane 3) mice after EcoRI/PstI restriction digestion and probing with an exon 2 PCR product. The wild type locus corresponds to the 3024-bp band, whereas the knock-out allele corresponds to the 5712-bp band. C, as for B after digestion with SacI and probing with an exon 6 PCR product, giving a 8567-bp band with the wild type allele and a 13,782-bp band with the knock-out allele. D, analysis of mRNA expression in knock-out mice. Shown is RT-PCR of total RNA extracted from liver of (lane 1) wild type, heterozygous (lane 2), and homozygous (lane 3) knock-out animals using primers amplifying between exons 2 and 6 of the mouse mutase locus together with control primers for the mouse Frda locus.
national, Temecula, CA) and ␤-mercaptoethanol. G418 (Invitrogen) antibiotic selection at 200 g/ml was added after 24 h and continued for 7 days. Resistant colonies were picked from day 6 to day 11. Cell lines were established and stored at Ϫ70°C. An aliquot of each line was seeded onto gelatin plates and grown to confluency. DNA was extracted and used for PCR screening to detect correct recombinants. Correctly targeted cell lines were initially determined by PCR using the primers sF, 5Ј-CAATAGAAGCCTTCCCAGAATG-3Ј, and sR, 5Ј-TTTTCTGGAT-TCATCGACTGT-3Ј, to give a product of 3 kb (Fig. 1C) .
Targeted cell lines were karyotyped and confirmed by fluorescent in situ hybridization and Southern blot analysis to contain a single targeting event (data not shown). Standard methods were used to microinject the targeted ES cell line into C57BL/6 blastocysts (10). These were transferred into pseudopregnant Swiss HSDOla-recipient mice. Chimeric mice were detected by coat color and mated with C57BL/6 mice to produce heterozygotes. Heterozygous progeny were interbred to produce homozygous knock-out mice.
Genotyping and Southern Analysis of Mice-DNA was extracted from mouse tail by standard methods and used for PCR genotyping (8) . Primers used for screening were as follows: neoF, 5Ј-CAACAGA-CAATCGGCTGCTC-3Ј; neoR, 5Ј-GTCACGACGAGATCCTCGC-3Ј (485 bp); expF, 5Ј-GGACCATATCCTACCATGT ATAC-3Ј; and expR, 5Ј-ACAGTGTCAATAGCAACTCCAG-3Ј (1243 bp). Southern blot analysis was performed on genomic DNA restriction digested with EcoRI and PstI and probed with a 250-bp exon 2 PCR fragment to confirm correct targeting of the 5Ј end of the construct. Correct targeting was confirmed at the 3Ј end by SacI digestion and probing with a 200-bp exon 6 PCR probe (Fig. 1C) .
RT-PCR Analysis-Total RNA was extracted from liver using the RNeasy kit (Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions. First strand synthesis was carried out with SuperScript TM RNase H reverse transcriptase kit (Invitrogen) using a random primer. PCR was carried out using primers 2F, 5Ј-CTTATAT-GGCACACCCCAGAA-3Ј, and 6R, 5Ј-TCCTGAATGATGATTCGTGTG-3Ј, for exons 2-6 (product length 1.2 kb) of the mouse mutase gene. Control RT-PCR for the mouse Frda mRNA was carried out with primers FATGCN-F, 5Ј-GCTCTCTAGAYGAGAC-3Ј, and FATGCN-R, 5Ј-CCCAAARGAGACATC-3Ј (product length 125 bp).
[ 14 C]Propionate Incorporation Assay-Fibroblast cultures were set up from skin biopsies. Cells were grown to confluence in 25-cm 2 flasks before trypsinization, splitting one-third, and incubation in a depleted medium (minimum Eagle's medium with added L-glutamine, non-essential amino acids, and fetal bovine serum) for 3 days. Cells were washed and incubated with labeled medium (Earl's balanced salt solution containing 200 nmol/ml propionate and 18 nmol/ml (1.0 mCi/ml) [ 14 C]propionate) for 18 h. Mutase activity was determined using the method of [ 14 C]propionate incorporation into trichloroacetic acid-precipitable material (11) . Incorporation was normalized with respect to protein content. Protein was determined using the Lowry method.
Analysis of Urine and Blood Metabolites-A 2-15-l urine sample was collected from each newborn pup and at various time points after birth within the first 24 h and was frozen until analysis. Organic acids were extracted with ethyl acetate, converted to trimethylsilyl derivatives, and analyzed by gas chromatography-mass spectrometry using an Agilent 5971 system (Palo Alto, CA) (12) . Selected ion monitoring at 287 m/z (methyl citric acid) and 247 m/z (methylmalonic acid) was performed.
For measurement of urine MM levels by electrospray tandem mass spectrometry, a 2-l volume of urine was mixed with 50 l of 100 M 2 H 3 -MM (MSD Isotopes, Montreal, Canada) and 220 l of 50% acetonitrile:water (v:v). A 30-l aliquot of this mixture was analyzed by flow injection into 80 l/min of 50% acetonitrile:water (v:v) infused into the ion source of a Quattro LC tandem mass spectrometer (Micromass, Manchester, United Kingdom) with multiple reaction monitoring for 117 Ͼ 73 m/z (MM) and 120 Ͼ 76 m/z ( 2 H 3 -MM). For the measurement of acylcarnitines by tandem mass spectrometry, blood was collected from newborn mice at various time points and spotted onto absorbent cotton fiber paper (Guthrie) cards. After drying, 3-mm spots were excised from the cards, extracted with methanol, and butylated in microtiter plates according to standard methods (13) . The same flow analysis parameters as above were used for the measurement of acylcarnitines, including the levels of C 3, C 2 , and C 0 carnitines. multiple reaction monitoring transitions (M ϩ H Ͼ 85 m/z) were used to measure the acylcarnitines.
Histopathology-Tissue samples were collected from culled mouse pups. Kidney, liver, and the intact brain were dissected and placed in 10% formalin. Coronal sections were taken from each organ of wild type mice, heterozygous mice, and homozygote knock-out mice at various times after birth and stained with hemotoxylin and eosin (H&E) or periodic acid Schiff reagent.
RESULTS
The targeting construct, pBR_mutB (Fig. 1B) , was designed to replace exon 3 of the mouse mutase locus with a neomycin/ kanamycin selection cassette, running in the reverse orientation, flanked by loxP sites. The exon 3 region is critical for CoA binding, and its disruption should result in a loss of function. Furthermore, even if the selection cassette was deleted by alternative splicing between exons 2 and 4, the deletion should lead to premature termination. A low targeting frequency in the order of 1 in 1000 was obtained between the targeting construct and homologous sequences in mouse ES cells. One correctly targeted ES cell line was identified by PCR screening, Southern blot analysis, and fluorescent in situ hybridization analysis (data not shown). However, the first chimeric animals generated after injection of this cell line into C57Bl/6 blastocysts were inexplicably lost over the first weeks after birth along with non-chimeric animals. No cause could be established for the loss of these animals. The injection was repeated and resulted in two germ line chimeras. These mice were crossed with C57BL/6 to produce heterozygous progeny and establish a healthy colony of heterozygous knock-out animals. Heterozygous knock-out animals are phenotypically normal and have normal growth and fertility. Heterozygous mice were intercrossed to produce homozygous progeny. Among 76 offspring from 12 littermates from such crosses, we identified by FIG. 3 . Analysis of urine metabolites in homozygous knock-out animals. A, gas chromatography-mass spectrometry-selected ion-monitoring chromatograms showing increase in MM and methylcitric (MC) acid levels in homozygous knock-out mice (KO) compared with wild type control mice (C). Methylcitric acid gives two peaks due to the formation of diastereoisomers. B, methylmalonic acid was measured by tandem mass spectrometry in urine samples of homozygous knock-out animals at various time points after birth. Accumulation of urinary MM in homozygous knock-out mice with time was observed.
PCR screening 17 animals that had the homozygous knock-out genotype ( Fig. 2A) , a result consistent with the expected Mendelian frequency. Southern blot analysis for the 5Ј and 3Ј ends of the targeting cassette gave the expected size fragments (Fig.  2, B and C) , also confirming homozygosity for the knock-out allele in affected neonates.
Homozygous null mice were born normally and were indistinguishable from their normal littermates at birth. They were of comparable birth weight and initially were active, vigorous, and suckled normally as evidenced by the observation of large milk spots in the stomach shortly after birth. By 15-18 h of age, homozygous null mice gradually became less active and stopped suckling (observation of pups behavior along with evidence of reduced/absent milk spots). Within a few hours, homozygous pups developed intermittent gasping respirations and had to be humanely sacrificed. Homozygous null mice did not survive beyond 24 h of age.
The mutase expression was examined in total RNA extracted from liver tissue of wild type, heterozygous, and homozygous knock-out mice. RT-PCR was performed using primers flanking the targeting cassette. No product was observed in homozygous mice. Control primers from the widely expressed Frda locus were used to confirm integrity of the RNA (Fig. 2D) .
Biochemical Characterization-Enzyme activity was assessed indirectly using [
14 C]propionate incorporation in cultured fibroblasts. Measurements were performed in duplicate, giving incorporation of 635 pmol propionate/mg protein/18 h in wild type mice compared with 39 pmol propionate/mg protein/18 h in homozygous knock-out mice. The residual enzyme activity detected in homozygous knock-out animals corresponded to only approximately 6% of the activity relative to wild type mice.
MM and methylcitric acid were grossly increased in urine as assessed by gas chromatography-mass spectrometry (Fig. 3A) . Measurement of urinary MMA levels collected at various time points post-delivery and measured using tandem mass spectrometry identified grossly elevated MM levels immediately after birth with a sequential increase over time (Fig. 3B) . There was no significant difference between levels in heterozygotes and wild type mice, although the method used may not have adequate sensitivity to detect small increases in heterozygotes.
Analysis of urine by dipstick showed a urinary pH of 6 with none of the urine samples tested (n ϭ 15), showing evidence of ketonuria. This included testing of urine samples immediately prior to death and with greatly elevated MM levels.
Analysis of acylcarnitines identified the mean of propionylcarnitine (C 3 ) levels to be approximately 6 times greater than mean levels in heterozygous and wild type mice (Table I) . There was no significant difference between knock-out and wild type mice for the other acylcarnitines. A comparison of the ratio of propionylcarnitine to free carnitine (C 3 :C 0) and to acetylcarnitine (C 3 :C 2) showed that these ratios were approximately 7-fold higher in homozygous mice when compared with unaffected controls (Table I) . These ratios have similarly been shown to be increased in human MMA subjects (14) .
Histology of the kidney showed no identifiable abnormality in homozygous mice. Sections were taken through five regions of the brain, and no gross histological abnormalities were detected on H&E stain (data not shown). Examination of liver samples taken within 12 h of birth was normal in homozygous knock-out animals in contrast to samples collected at around 20 h of age, which showed evidence of moderate fatty change in liver parenchyma (Fig. 4) .
DISCUSSION
Mice homozygous for the knock-out allele demonstrate a phenotype similar to that of the human mut 0 MMA. As frequently occurs with the human MMA disorder, they are born normally and develop disease in the newborn period once they are removed from the maternal circulation and commence ingestion of protein. The maternal circulation in this model also appears to be protective of the fetus, at least to the extent that mice develop normally in utero and are born healthy. Nevertheless, levels of MMA in the urine are already significantly elevated even with the first sample collected straight after birth. This suggests the maternal circulation does not completely "detoxify" the fetus. This finding is in agreement with the observed elevation of odd-numbered long-chain fatty acids in fetuses in disorders of propionate metabolism, reflecting the ongoing in utero elevation of propionyl-CoA despite the maternal circulation (15) . The significance of this to the health of the developing fetus is unclear at this stage.
Studies of RNA by RT-PCR in these mice failed to show any mutase product in homozygotes. The targeting cassette was designed such that if the antibiotic marker was alternatively spliced the resulting product would result in a frameshift with a premature termination codon. We postulate that no product was produced as a result of unstable RNA and nonsense-mediated decay. In keeping with the null genotype was the [
14 C]propionate incorporation, indicating a marked reduction in MCM activity.
Biochemically, these mice demonstrate the characteristic biochemical changes observed in MMA. They have elevated urinary levels of methylmalonic and methylcitric acids and an elevation in blood of C 3 or propionylcarnitine in the range observed with human disease (12, 14) . The C 3 :C 2 and C 3 :C 0 ratios, which are used as another indicator for the identification of the organic acid disorders MMA and propionic acidemia (PA) in newborn-screening programs, are also elevated in our animal model. FIG. 4 . Histological analysis of liver sections in homozygous knock-out mice. H&E stain of liver tissue collected immediately postculling from wild type mouse and homozygous knock-out mice at Ͻ12 h and ϳ20 h of age, showing moderate fatty change in sample at ϳ20 h.
TABLE I Measurement of acylcarnitines by tandem mass spectrometry in mouse blood
The free carnitine (C 0 ), acetylcarnitine (C 2 ), and propionylcarnitine (C 3 ) values were measured in blood samples from five homozygous knock-out mice (mut Ϫ/Ϫ ) and four control mice. The C 3 carnitine levels (in m) (mean Ϯ S.D.) are shown as well as the C 3 :C 0 and C 3 :C 2 ratios. Only propionylcarnitine values are elevated (p ϭ 0.002) in homozygous knock-out animals. 
